Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Target Occupancy PET Study of Xanamem

Trial Profile

A Phase 1 Target Occupancy PET Study of Xanamem

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs UE 2343 (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 03 Jul 2019 According to an Actinogen Medical media release, the study has now completed the 20mg cohort and the Company is pleased to confirm that the results continue to be encouraging, with this dose also demonstrating significant inhibition of the 11beta-HSD1 enzyme. The study will now proceed with 30mg and 5mg cohorts, to enable a full analysis and understanding of the dose-inhibition response of Xanamem.
    • 26 Jun 2019 Results (10mg ) presented in an Actinogen Medical media release.
    • 26 Jun 2019 According to an Actinogen Medical media release, further results are expected by mid Q3 and Q4 CY2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top